骨髓增生异常综合征患者HLA-DR15基因的表达

Human leukocyte antigen-DR15 gene expression in patients with myelodysplastic syndrome

目的探讨骨髓增生异常综合征(MDS)患者HLA-DR15基因的表达状况。方法采用聚合酶链反应-序列特异性引物(PCR-SSP)检测MDS患者(n=59)HLA-DR15基因的表达,并与健康对照组(n=104)进行比较。结果MDS组HLA-DR15基因表达率为44.07%,明显高于健康对照组的12.5%(P<0.01)。其中难治性贫血(RA)患者HLA-DR1的表达率为16/34,环状铁粒幼细胞性贫血(RAS)患者为4/6,原始细胞过多难治性贫血及其转化型(RAEB/RAEB-T)患者为4/12,CMML患者为2/7。低危组HLA-DR15表达比例高于高危组(P<0.05)。MDS核型异常和核型正常者HLA-DR15基因表达无差异(P>0.05)。结论MDS患者HLA-DR15阳性率明显增高;HLA-DR15基因可能是MDS的易感基因,可能可作为MDS的一个预后评价指标。

Objective To study the expression of human leukocyte antigen-DR15 （HLA-DR15） gene in patients with myelodysplastic syndrome （MDS）. Methods HLA-DR15 was detected by the technique of polymerase chain reaction-sequence specific primers（ PCR- SSP） and compared between peripheral blood of MDS group（ n = 59） and control group（ n = 104）. Results In the MDS group, the gene frequency of HLA-DR15 （44.07%） was significantly higher than that in the control group （ 12.5% ） （P 〈 0.01 ）. There were 16 patients with HLA-DR15 in group of refractory anemia （RA, n =34）. Four of 6 cases with refractory anemia with ringed sideroblasts （RAS） were positive for HLA-DR15. In group of refractory anemia with excess of blasts（ RAEB）, 4 of 12 had HLA-DR15 gene. While the ratio which expressed HLA-DR15 in chronic myelomonocytic leukaemia （CMML） was 2/7. The low risk group had significantly higher frequency of HLA-DR15 than that of high risk group （P 〈 0.05）. There was no difference in frequency of HLA-DR15 between cytogenetic abnormality and normality groups （P 〉 0.05）. Conclusion The expression of HLA-DR15 gene is higher in MDS patients than in normal controls. HLA-DR15 may serve as a prognostic predicting factor for MDS.